As early as May 2020, Jilin Heart Hospital exclusively contributed 18.1% of the scientific experimental data. To date, as a primary contributor to the ROMA Trial, Jilin Heart Hospital has enrolled 790 patients, making it the top global recruiter among all participating centers. Due to its outstanding performance, Jilin Heart Hospital has become one of the leading participants in the ROMA Trial, making exceptional contributions to the development and research of human cardiac surgery.
The Perceval S sutureless aortic valve replacement is an innovative surgical approach that can shorten cardiopulmonary bypass and aortic cross-clamp times, thereby benefiting patients undergoing the procedure.
More than 80 cardiac surgery experts from hospitals in over 30 provinces and cities across China gathered at Jilin Heart Hospital to participate in technical training. Among these institutions were industry leaders such as Fuwai Hospital, Beijing Anzhen Hospital, and Beijing 301 Hospital, as well as hospitals representing the highest-level cardiac medical institutions in their respective provinces and cities, including the First Affiliated Hospital of Zhejiang University School of Medicine, the First Affiliated Hospital of Xi'an Jiaotong University, Xijing Hospital, the Second Xiangya Hospital of Central South University, and Zhongshan Hospital affiliated with Fudan University.